Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study

Yi-Wen Huang; Pei-Jer Chen; Chao Wei Hsu; Sheng-Nan Lu; Ming-Lung Yu; Chien-Wei Su; Wei-Wen Su; Rong-Nan Chien; Ching-Sheng Hsu; Shih-Jer Hsu; Hsueh-Chou Lai; Kuan-Chiao Tseng

Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study

Yi-Wen Huang, Pei-Jer Chen, Chao Wei Hsu, Sheng-Nan Lu, Ming-Lung Yu, Chien-Wei Su, Wei-Wen Su, Rong-Nan Chien, Ching-Sheng Hsu, Shih-Jer Hsu, Hsueh-Chou Lai, Kuan-Chiao Tseng

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Hepatology
Volume	66
Issue number	6
State	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Huang, Y.-W., Chen, P.-J., Hsu, C. W., Lu, S.-N., Yu, M.-L., Su, C.-W., Su, W.-W., Chien, R.-N., Hsu, C.-S., Hsu, S.-J., Lai, H.-C., & Tseng, K.-C. (2017). Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study. Hepatology, 66(6).

@article{9664b21e182046fa955d28ede663d547,

title = "Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study",

author = "Yi-Wen Huang and Pei-Jer Chen and Hsu, \{Chao Wei\} and Sheng-Nan Lu and Ming-Lung Yu and Chien-Wei Su and Wei-Wen Su and Rong-Nan Chien and Ching-Sheng Hsu and Shih-Jer Hsu and Hsueh-Chou Lai and Kuan-Chiao Tseng",

year = "2017",

language = "American English",

volume = "66",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study. / Huang, Yi-Wen; Chen, Pei-Jer; Hsu, Chao Wei et al.
In: Hepatology, Vol. 66, No. 6, 2017.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naive patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study

AU - Huang, Yi-Wen

AU - Chen, Pei-Jer

AU - Hsu, Chao Wei

AU - Lu, Sheng-Nan

AU - Yu, Ming-Lung

AU - Su, Chien-Wei

AU - Su, Wei-Wen

AU - Chien, Rong-Nan

AU - Hsu, Ching-Sheng

AU - Hsu, Shih-Jer

AU - Lai, Hsueh-Chou

AU - Tseng, Kuan-Chiao

PY - 2017

Y1 - 2017

M3 - Journal Article

SN - 0270-9139

VL - 66

JO - Hepatology

JF - Hepatology

IS - 6

ER -